Discussions are underway in and outside the pharmaceutical industry to explore a new NHI price revision method for listed medicines that could replace the current rules based on market prices. Parties like the Study Group on Drug Pricing and Distribution…
HOME > ACADEMIA
ACADEMIA
- Emergency Approval Push for Shionogi’s COVID Pill Not Profit-Driven: Academic Societies
September 9, 2022
- University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
- Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
- Japanese Society of Formulary to Support Regional Initiatives: President
August 18, 2022
- Japan Pediatric Society Recommends COVID Jab for Ages 5-17
August 12, 2022
- High Hopes for Sanofi’s Enjaymo as Japan’s First CAD Therapy: Osaka University Professor
August 5, 2022
- 7 Japan Scientific Societies Issue Proposal on Development of Vaccines, Anti-Infectives
August 3, 2022
- Deregulation Likely to Create 1.15 Trillion Yen Headroom for Switched OTC Growth: Health Economist
July 15, 2022
- Gynecologist Cautious about Inclusion of Pregnant Women in Clinical Trials, but Says ICH Move Will Spark Safety Discussions
July 14, 2022
- Bromocriptine Found to Slow Alzheimer’s Progression: Kyoto University
July 1, 2022
- NCC Doctor Hails MHLW’s Policy on Use of Clinical Research Data in Regulatory Filing
June 22, 2022
- Kitasato University Spinoff PRD to Develop Lipid Metabolism Control Agents
June 10, 2022
- NCGM, IQVIA Pair Up to Unravel “Long COVID” by Building Large-Scale Registry
May 31, 2022
- A Dozen Regional Formularies to Be Launched by Year-End, Pharmacists Must Take the Lead: Society Chief
May 25, 2022
- Difficult-to-Quantify Factors Should Be Reflected in Drug Prices to Establish VBP: Health Economist
May 9, 2022
- 5 Academic Societies Prod Price Rethink for 32 Key Antibiotics to Stabilize Supply
May 9, 2022
- Insurance Coverage of Fertility Treatments Could Reduce Patients’ Payments by 20-30%: Obstetrician
April 11, 2022
- Ex-JAMS President Fumimaro Takaku Dies at 91
March 28, 2022
- Exon 44-Targeted DMD Drug Hits Goals in PI/II: NCNP/Nippon Shinyaku
March 18, 2022
- Japan Researchers Test Efficacy of COVID Drugs for BA.2 Omicron Subvariant
March 11, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…